Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
The chart shows the growth of an initial investment of $10,000 in Axsome Therapeutics, Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Axsome Therapeutics, Inc (AXSM) has returned -8.09% so far this year and 78.37% over the past 12 months. Looking at the last ten years, AXSM has achieved an annualized return of 33.69%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Axsome Therapeutics, Inc (AXSM) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.50% | -11.11% | 4.29% | -1.16% | ||||||||
| 2025 | 24.88% | 20.32% | -10.28% | -0.12% | -5.44% | -0.92% | -2.54% | 19.71% | 0.03% | 10.20% | 22.28% | 21.76% |
| 2024 | 14.54% | -10.11% | -1.63% | -7.57% | -0.81% | 8.30% | 9.08% | 1.43% | -0.14% | -1.31% | 10.29% | -12.94% |
| 2023 | -3.47% | -9.32% | -9.08% | 15.88% | 2.92% | -3.10% | 9.20% | 3.06% | -14.39% | -11.03% | 8.81% | 17.95% |
| 2022 | -27.66% | 2.44% | 43.62% | -24.08% | -19.64% | 51.68% | 1.34% | 65.93% | -28.94% | -0.88% | 57.15% | 6.93% |
| 2021 | -16.26% | -3.08% | -15.84% | 5.46% | -1.35% | 9.96% | -27.26% | -47.88% | 27.01% | 16.31% | -10.45% | 8.07% |
| 2020 | -17.07% | -11.15% | -25.93% | 68.31% | -16.78% | 6.82% | -13.38% | 2.39% | -3.40% | -7.45% | 8.23% | 6.83% |
| 2019 | 198.58% | -5.46% | 78.54% | 23.99% | 29.35% | 12.54% | -3.08% | -0.97% | -19.91% | 18.91% | 62.42% | 156.41% |
| 2018 | -50.44% | -7.27% | -2.00% | 38.78% | -2.90% | -4.48% | -16.67% | 32.69% | -1.43% | 11.53% | -16.20% | -14.55% |
| 2017 | -30.00% | -7.14% | -17.02% | 2.50% | -4.94% | 42.86% | 10.91% | -17.07% | 7.77% | -13.64% | 18.95% | 4.67% |
| 2016 | 33.14% | -34.31% | -3.83% | 4.41% | -5.36% | 8.69% | -14.65% | -4.38% | 3.05% |
The charts below present risk-adjusted performance metrics for Axsome Therapeutics, Inc (AXSM) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of AXSM compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Axsome Therapeutics, Inc volatility is 2.38%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 689.81M | 568.50M | 588.24M | 331.48M | 87.79M | 186.13M | 220.55M | 15.38M | 35.56M | 38.21M |
| Equity Attributable To Parent (USD) | 88.30M | 57.02M | 190.98M | 109.56M | 15.63M | 113.79M | 178.72M | 937.92K | 16.72M | 21.57M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 88.30M | 57.02M | 190.98M | 109.56M | 15.63M | 113.79M | 178.72M | 937.92K | 16.72M | 21.57M |
| Noncurrent Liabilities (USD) | 222.67M | 281.38M | 258.41M | 125.36M | 49.09M | 48.90M | 17.33M | 3.62M | 6.66M | 9.47M |
| Other Current Liabilities (USD) | 276.36M | 129.88M | 77.72M | 46.67M | 5.87M | 7.06M | 11.50M | 6.08M | 8.04M | 2.55M |
| Wages (USD) | 36.94M | 28.23M | 20.46M | 11.28M | 4.05M | 2.87M | 2.06M | 1.05M | 704.56K | 539.29K |
| Accounts Payable (USD) | 65.54M | 72.00M | 40.68M | 38.61M | 13.15M | 13.50M | 10.94M | 3.69M | 3.44M | 4.08M |
| Current Liabilities (USD) | 378.84M | 230.10M | 138.85M | 96.56M | 23.07M | 23.44M | 24.49M | 10.82M | 12.18M | 7.17M |
| Liabilities (USD) | 601.51M | 511.48M | 397.26M | 221.92M | 72.15M | 72.34M | 41.83M | 14.44M | 18.84M | 16.64M |
| Other Non-current Assets (USD) | 59.74M | 35.96M | 29.84M | 25.45M | 983.07K | 2.06M | 139.88K | 112.35K | 187.95K | 112.82K |
| Intangible Assets (USD) | 40.52M | 46.89M | 53.29M | 59.66M | - | - | - | - | - | - |
| Fixed Assets (USD) | 562.00K | 584.00K | 846.00K | 722.52K | 283.85K | 52.65K | 30.62K | 51.83K | 68.07K | 100.73K |
| Noncurrent Assets (USD) | 100.82M | 83.43M | 83.97M | 85.83M | 1.27M | 2.11M | 170.50K | 164.18K | 256.02K | 213.55K |
| Other Current Assets (USD) | 561.05M | 469.33M | 489.13M | 241.32M | - | - | - | - | - | - |
| Inventory (USD) | 27.94M | 15.73M | 15.14M | 4.32M | - | - | - | - | - | - |
| Current Assets (USD) | 588.99M | 485.06M | 504.26M | 245.64M | 86.52M | 184.02M | 220.38M | 15.22M | 35.30M | 38.00M |
| Assets (USD) | 689.81M | 568.50M | 588.24M | 331.48M | 87.79M | 186.13M | 220.55M | 15.38M | 35.56M | 38.21M |
Summit Therapeutics faces significant near-term risk as its FDA decision on ivonescimab is expected by November 14, 2026. The drug failed to demonstrate statistically significant overall survival improvement in non-Chinese patient populations, which the FDA requires for approval. Meanwhile, Axsome Therapeutics and Madrigal Pharmaceuticals are positioned to potentially outperform Summit by year-end, driven by upcoming catalysts and strong revenue growth.
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.
Two biotech companies are highlighted as standout investments for 2026. Axsome Therapeutics has strong late-stage pipeline developments with FDA acceptance of supplemental applications for AXS-05 in Alzheimer's agitation treatment and support for AXS-12 for narcolepsy, with 19 of 20 analysts rating it a Buy and targeting 8% upside. Innoviva received FDA approval for Nuzolvence, a first-in-class oral antibiotic for gonorrhea with significant market potential, and has shown strong financial performance with analyst consensus price target nearly double current trading levels.
The Motley Fool recommends two biotech stocks for long-term investment: Axsome Therapeutics, which has generated strong revenue growth (65.8% YoY through Q3 2025) with approved products and promising late-stage candidates including Auvelity for Alzheimer's disease agitation; and Exelixis, an oncology specialist with its blockbuster drug Cabometyx and an upcoming next-generation cancer medicine Zanzalintinib in phase 3 trials for metastatic colorectal cancer.
Axsome Therapeutics announced that the FDA has accepted and granted Priority Review designation to its supplemental NDA for AXS-05 for treating Alzheimer's disease agitation, with a PDUFA target action date of April 30, 2026. The drug addresses a significant unmet medical need, as up to 76% of Alzheimer's patients experience agitation. AXS-05 previously received Breakthrough Therapy designation in June 2020.
The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.
Axsome Therapeutics will participate in two investor conferences in December 2025, including the Piper Sandler Healthcare Conference and BofA Securities CNS Therapeutics Virtual Conference, presenting their latest developments in central nervous system treatments.
Two biotech companies, Axsome Therapeutics and Exelixis, are predicted to potentially outperform the market in the next five years due to strong product portfolios, promising drug pipelines, and potential for significant market expansion in healthcare treatments.
Law firm Johnson Fistel is investigating potential legal violations by officers of General Motors, DocGo, Estée Lauder, and Axsome Therapeutics, with class action lawsuits surviving motions to dismiss.
Axsome Therapeutics announced participation in multiple healthcare investor conferences in September 2025, including Wells Fargo, Cantor, Morgan Stanley, and others, presenting fireside chats and investor meetings.
